NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

This study is testing whether chemotherapy combined with immunotherapy before surgery (neoadjuvant treatment) can make inoperable pleural mesothelioma (a rare cancer of the lining of the lungs) operable. Patients whose tumors shrink enough after treatment may then proceed to surgery. This is a selected, carefully evaluated group of patients with potentially resectable disease. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of epithelioid pleural mesothelioma (PM), stage cT2-3 N0-1 M0 - Your cancer was assessed as inoperable by a multidisciplinary tumor board at UZA or UZG at the start of the trial - Your general health allows you to receive chemotherapy, immunotherapy, and potentially surgery (WHO performance status 0–1) - You have provided written informed consent **You may NOT be eligible if...** - You have a non-epithelioid mesothelioma subtype (e.g., sarcomatoid) - Your cancer has spread beyond stage T3 or to distant sites (M1) - You are already considered operable before starting treatment - You have serious active infections, other cancers, or organ dysfunction Talk to your doctor to see if this trial is right for you.